Physician profile
John W Thames
NPI 1689057721
$3,496.90
in general payments reported to CMS, 2019-2025
27 companies · $626 in 2025
The $626 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $441 · 2021: $543 · 2022: $554 · 2023: $594 · 2024: $583 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $744.64 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $611.12 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $362.67 | 2019-2025 | |
| Lilly USA, LLC | $290.38 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $279.44 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Abbott Laboratories | $145.48 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $117.03 | 2020-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $88.05 | 2022 | |
| Vanda Pharmaceuticals INC. | $80.07 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $75.74 | 2019-2023 | |
| Amgen INC. | $74.95 | 2022-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $73.15 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $71.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Paratek Pharmaceuticals, INC. | $67.46 | 2021-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $58.27 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $53.86 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.15 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.09 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.63 | 2024-2025 | Caplyta |
| Shionogi INC | $32.36 | 2019 | |
| Idorsia Pharmaceuticals US INC | $27.08 | 2023 | Quviviq |
| Medtronic, INC. | $24.67 | 2022 | |
| Allergan, INC. | $24.05 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $15.59 | 2025 | Contrave, Onzetra Xsail |
| Sanofi Pasteur INC. | $14.24 | 2019 | |
| Genentech USA, INC. | $11.00 | 2019 | |
| Shire North American Group INC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.